HIV
India already has a homegrown CAR T-cell therapy, and other regions are exploring their own strategies, including developing them at the point of care.
Immunocore Outlines Strategic Priorities on Kimmtrak and TCR Therapy Pipeline
The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that patients outside of cancer may not accept.
Helocyte Gains Rights to Use City of Hope's CMV Vaccine to Boost CAR T-Cell Therapy Efficacy in HIV
Based on preclinical data, experts believe the cancer center's Triplex cytomegalovirus vaccine can stimulate CMV/HIV-CAR T cells to proliferate in patients.
HIV Gene Therapy Developer Addimmune to Go Public Through SPAC Merger
Addimmune, a company launched from American Gene Technologies' HIV drug development program, plans to trade under the ticker symbol "HIV."